Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program
Creative Medical Technology Holdings (NASDAQ: CELZ) has initiated a program to diagnose and treat patients exposed to biological and chemical weapons. The program combines Artificial Intelligence (AI) with the company's proprietary human induced pluripotent stem cells (iPSC) from its iPSCelz® program. AI will be used to identify damage in exposed patients, and based on the clinical diagnosis, the company's validated iPSC Inducible Pluripotent Mesenchymal Cells will be used for personalized treatment. This initiative aligns with Creative Medical Technology's focus on regenerative approaches to immunotherapy, urology, neurology, and orthopedics.
Creative Medical Technology Holdings (NASDAQ: CELZ) ha avviato un programma per diagnosticare e trattare pazienti esposti a armi biologiche e chimiche. Il programma combina Intelligenza Artificiale (IA) con le cellule staminali pluripotenti indotte umane (iPSC) proprietarie dell'azienda, provenienti dal programma iPSCelz®. L'IA sarà utilizzata per identificare i danni nei pazienti esposti e, sulla base della diagnosi clinica, saranno utilizzate le Cellule Mesenchimali Pluripotenti Inducibili iPSC convalidato per un trattamento personalizzato. Questa iniziativa è in linea con l'attenzione di Creative Medical Technology per approcci rigenerativi all'immunoterapia, urologia, neurologia e ortopedia.
Creative Medical Technology Holdings (NASDAQ: CELZ) ha iniciado un programa para diagnosticar y tratar a pacientes expuestos a armas biológicas y químicas. El programa combina Inteligencia Artificial (IA) con las células madre pluripotentes inducidas humanas (iPSC) patentadas de la empresa, provenientes de su programa iPSCelz®. Se utilizará IA para identificar daños en los pacientes expuestos y, según el diagnóstico clínico, se utilizarán las Células Mesenquimatosas Pluripotentes Inducibles iPSC validadas para un tratamiento personalizado. Esta iniciativa se alinea con el enfoque de Creative Medical Technology en enfoques regenerativos para la inmunoterapia, urología, neurología y ortopedia.
Creative Medical Technology Holdings (NASDAQ: CELZ)가 생물학적 및 화학적 무기에 노출된 환자를 진단하고 치료하는 프로그램을 시작했습니다. 이 프로그램은 인공지능(AI)과 회사의 독점 인간 유도 다능성 줄기세포(iPSC)를 결합합니다. AI를 사용하여 노출된 환자의 손상을 식별하고, 임상 진단에 따라 회사의 검증된 iPSC 유도 다능성 중간엽 세포를 개인 맞춤형 치료에 사용할 것입니다. 이 이니셔티브는 Creative Medical Technology의 면역요법, 비뇨기과, 신경학 및 정형외과에 대한 재생 접근법에 대한 집중과 일치합니다.
Creative Medical Technology Holdings (NASDAQ: CELZ) a lancé un programme pour diagnostiquer et traiter les patients exposés à des armes biologiques et chimiques. Le programme combine Intelligence Artificielle (IA) avec les cellules souches pluripotentes induites humaines (iPSC) propriétaires de l'entreprise, issues de son programme iPSCelz®. L'IA sera utilisée pour identifier les dommages chez les patients exposés, et en fonction du diagnostic clinique, les Cellules Mésenchymateuses Pluripotentes Inducibles iPSC validées seront utilisées pour un traitement personnalisé. Cette initiative s'inscrit dans l'orientation de Creative Medical Technology vers des approches régénératrices de l'immunothérapie, de l'urologie, de la neurologie et de l'orthopédie.
Creative Medical Technology Holdings (NASDAQ: CELZ) hat ein Programm zur Diagnose und Behandlung von Patienten, die chemischen und biologischen Waffen ausgesetzt waren, initiiert. Das Programm kombiniert Künstliche Intelligenz (KI) mit den firmeneigenen human induzierten pluripotenten Stammzellen (iPSC) aus dem iPSCelz®-Programm. KI wird verwendet, um Schäden bei den exponierten Patienten zu identifizieren, und basierend auf der klinischen Diagnose werden die validierten iPSC induzierbaren pluripotenten mesenchymalen Zellen für eine personalisierte Behandlung eingesetzt. Diese Initiative steht im Einklang mit dem Fokus von Creative Medical Technology auf regenerative Ansätze in der Immuntherapie, Urologie, Neurologie und Orthopädie.
- Initiation of a new program for diagnosing and treating biological and chemical weapon exposure
- Utilization of AI technology for damage assessment in exposed patients
- Integration of proprietary iPSC technology for personalized treatment
- Expansion into a potentially high-demand medical field
- None.
PHOENIX, July 24, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a leading commercial-stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that it has initiated its planned program to diagnose and treat patients exposed to biological and chemical weapons by combining Artificial Intelligence (AI) with the Company’s proprietary human induced pluripotent stem cells (“iPSC”). This iPSC clinical line is part of the Company’s iPSCelz® program.
“The program is designed to utilize the predictive capabilities of AI to identify damage to patients exposed to biological or chemical weapons and, based on a clinical diagnosis supported by that assessment, use the Company’s validated iPSC Inducible Pluripotent Mesenchymal Cells to treat these individuals on a patient-by-patient basis,” said Timothy Warbington, CEO of Creative Medical Technology.
About Artificial Intelligence in Medicine
Artificial Intelligence (AI) is changing biotechnology by strengthening research efficiency, precision, and innovation. In drug discovery, AI accelerates the identification of potential targets and optimizes biological screenings, significantly shortening development timelines. ImmCelz® and iPSCelz® benefit from AI's ability to analyze vast genetic data, enabling the creation of tailored treatment plans based on individual genetic profiles. Predicting the interaction between compounds and target proteins will help Creative Medical Technology optimize quality and quantity, helping to maximize the Company’s resources.
About our Validated iPSC Programs
The iPSC clinical line, derived from the company’s Mesenchymal Cell (MSC) program currently utilized in several of our FDA-cleared clinical programs in the U.S., has also been used to derive validated mesenchymal and T-regulatory cells. This technology is a key component in the individualized treatment of such biological and chemical exposure.
“Based on the successful development of our iPSC MSCs and the use of AI in our process, having filed patents and possessing substantial trade secrets (2022 and 2023), this program is within our budget and ready to begin,” continued Mr. Warbington. “With a strong current cash position and no need to raise funds at this time, the Company continues to achieve significant milestones with its multiple programs in a cost-efficient manner without sacrificing quality and maintaining strict adherence to all regulatory requirements.”
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a commercial-stage biotechnology company specializing in stem cell technology in the fields of immunotherapy, urology, neurology, and orthopedics. For further information about the Company, please visit www.creativemedicaltechnology.com.
Forward Looking Statements
This news release may contain forward-looking statements, including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions, which may involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.
Company Contact Investor Relations
Creative Medical Technology Devin Sullivan, Managing Director
IR@CreativeMedicalTechnology.com The Equity Group Inc.
dsullivan@equityny.com
Conor Rodriguez, Analyst
crodriguez@equityny.com
FAQ
What new program has Creative Medical Technology Holdings (CELZ) initiated?
How does Creative Medical Technology Holdings (CELZ) plan to use AI in their new program?
What is the iPSCelz® program mentioned in the CELZ press release?
How does Creative Medical Technology Holdings (CELZ) plan to treat patients in their new program?
